Ameriprise Financial Inc. Raises Position in IQVIA Holdings Inc. (NYSE:IQV)

Ameriprise Financial Inc. lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 971,133 shares of the medical research company’s stock after acquiring an additional 14,004 shares during the period. Ameriprise Financial Inc.’s holdings in IQVIA were worth $190,838,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in IQV. Synergy Asset Management LLC acquired a new stake in IQVIA in the 4th quarter worth about $33,000. GKV Capital Management Co. Inc. purchased a new position in shares of IQVIA during the 4th quarter worth about $39,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA in the fourth quarter worth approximately $44,000. Zions Bancorporation N.A. grew its holdings in IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 85 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in IQVIA during the fourth quarter worth approximately $60,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on IQV shares. UBS Group lowered their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Morgan Stanley upped their price target on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Stifel Nicolaus cut their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Barclays reiterated an “equal weight” rating and set a $170.00 target price (down previously from $235.00) on shares of IQVIA in a report on Thursday, April 10th. Finally, StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $237.62.

IQVIA Stock Performance

Shares of IQV opened at $146.12 on Wednesday. The firm has a market cap of $25.76 billion, a price-to-earnings ratio of 19.48, a PEG ratio of 1.99 and a beta of 1.34. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The business’s 50 day moving average is $165.94 and its two-hundred day moving average is $189.86. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.